Emyria Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

EmyriaDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -20.9% zurückgegangen, während in der Branche Pharmaceuticals die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 0.7% pro Jahr.

Wichtige Informationen

-22.7%

Wachstumsrate der Gewinne

-3.7%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	31.2%
Wachstumsrate der Einnahmen	20.7%
Eigenkapitalrendite	-472.3%
Netto-Marge	-520.1%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie Emyria Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

ASX:EMD Einnahmen, Ausgaben und Erträge (AUD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	2	-11	2	0
31 Mar 24	2	-12	2	0
31 Dec 23	2	-12	2	0
30 Sep 23	2	-9	2	0
30 Jun 23	2	-5	2	0
31 Mar 23	2	-6	2	1
31 Dec 22	2	-8	2	2
30 Sep 22	2	-7	3	2
30 Jun 22	2	-7	3	1
31 Mar 22	2	-7	3	1
31 Dec 21	2	-6	3	1
30 Sep 21	2	-6	2	1
30 Jun 21	2	-5	2	1
31 Mar 21	2	-5	2	1
31 Dec 20	2	-5	1	1
30 Sep 20	1	-5	2	1
30 Jun 20	1	-5	2	1
31 Mar 20	1	-5	2	1
31 Dec 19	1	-4	2	0
30 Sep 19	0	-3	2	0
30 Jun 19	0	-3	1	0

Qualität der Erträge: EMD ist derzeit unrentabel.

Wachsende Gewinnspanne: EMD ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: EMD ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 20.9% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von EMD verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: EMD ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (28.2%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: EMD hat eine negative Eigenkapitalrendite (-1258.13%), da es derzeit unrentabel ist.

Emyria Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Recent updates

New minor risk - Share price stability

Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)

New major risk - Market cap size

Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.

New major risk - Financial position

New minor risk - Share price stability

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Emyria Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Emyria Limited Announces Strategic Board Transition

Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million.

Emyria Limited Secures Clinical-Grade MDMA Supply for Aust Patients

Emyria Limited Expands MDMA Programs Following Landmark TGA Decision

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

Emyria Limited Announces Commencement of First Dosing for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Its Acceptance into the Preclinical Screening Platform for Pain Program

Less than half of directors are independent

Emyria Limited and The University of Western Australia Expands Unique MDMA

Emyria Expands Clinical Sites for EMD-RX5 Phase 3 Trial

Emyria Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Emyria Limited Receives Ethics Approval for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Initiation of Human Cell-Line Preclinical Studies to Advance Its Mdma-Inspired Drug Discovery Partnership with the University of Western Australia

Emyria Limited Announces Positive Progress of its Preclinical MDMA Analogue Medicine Program

Emyria Limited Reports Positive Phase 1 Trial Data for EMD-RX5 Indicating Ideal Bioavailability, Safety and Tolerability Among 12 Healthy and Demographically Diverse Volunteer Subjects

We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely

Emyria Limited Receives Further Positive MDMA Analogue Screening Results

Less than half of directors are independent

Emyria Limited Announces EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial

Emyria Limited Commences Dosing for EMD-RX5 Phase 1 Human Clinical Trial

Emyria Limited Commences for the EMD-RX5 Clinical Development Program

Emyria Limited Ethics Approval Receives for EMD-RX5 Phase 1 Study

Emyria Limited Announces Substantial Expansion of Proprietary MDMA Analogue Library Being Created with the University of Western Australia

Emyria Limited Announces Phase 1 Clinical Trials to Commence for Its Leading Ultra-Pure CBD Drug Candidate, Referred to as EMD-RX5

Emyria Limited announced that it expects to receive AUD 5 million in funding from Tattarang Pty Ltd

Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Limited Provides Novel Mdma Analogue Screening Program Advanced Update

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Executes Pure CBD Agreement with Altasciences to Accelerate FDA and TGA Cannabinoid Registration Programs

Emyria Advances EMD-004 Program Towards Registration

We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully

Emyria Limited and Mind Medicine Australia Launch MDMA-Assisted Therapy Program for PTSD

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Emyria Limited Announces the Appointment of Dr. Karen Smith to Chair the Company's Strategic Advisory Board

New 90-day high: AU$0.23

Emyria Limited Wins Digital Health Monitoring Grant with UWA

Emyria Limited Appoints Dr Richard Magtengaard, to Its Medical Advisory Board

Emyria Limited to Pursue Registration of EMD-003 with Australia's Therapeutic Goods Administration in 2021

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.

Emyria Limited Launches Drug Development Program Based on RWE

Emyria Limited Partners with Mind Medicine Australia

Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares

Executive Chairman recently bought AU$61k worth of stock

Emyria Limited Enters Data Deal with Zelira to Support Autism Trial

Zelira Therapeutics Ltd Enters into Agreement with Emyria Ltd

Emerald Clinics Limited to Report Fiscal Year 2020 Results on Oct 30, 2020

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite